

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Jaime Moriguchi

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Medical Director, Mechanical Circulatory Support Program

Director, Advanced Heart Failure Outreach Program

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
Stanford University, Stanford, CA	BS	1977	
University of California Los Angeles, Los Angeles, CA	MD	1981	Medicine
University of California Los Angeles, Los Angeles, CA		1982	Internship
University of California Los Angeles, Los Angeles, CA		1984	Residency
University of California Los Angeles, Los Angeles, CA		1987	Fellowship

A. Personal Statement

Following completion of formal training at the David Geffen-UCLA School of Medicine, I completed a general internal medicine residency and cardiology fellowship including a year where I served as Chief Resident at the Ronald Reagan-UCLA Medical Center. I then joined the University Cardiovascular Medical Group (Cal Heart) and helped to create the UCLA Heart Transplant, HF/CMY and MCS programs. We were fortunate enough to grow into one of the largest programs in the world with excellent clinical outcomes. In 2010, our team moved to Cedars-Sinai Medical Center, where we continue to grow, performing 120-130 heart transplants annually with 1 yr actuarial survival of 92%. Throughout this journey, my passion and energy has been devoted to the mechanical circulatory support (MCS) program serving as the Medical Director. The majority of our patients are critically ill with cardiogenic shock and we have developed a very strong VA ECMO and percutaneous MCS program as bridge to transplantation (BTT). We also implant durable LVADs for destination therapy and BTT. Over the past 7 yrs, we have also become one of the largest total artificial heart programs in the US (~100 implants).

This past year, I was also appointed as the Director of Advanced Heart Failure Outreach, which is another passion of mine. Our main mission is to establish advanced heart failure outreach centers throughout Southern California which are designed to evaluate, manage and facilitate expeditious transfers of appropriate patients to our center for advanced heart failure therapies. Our group is also heavily dedicated to clinical research in heart transplantation, heart failure and MCS and are involved in numerous national/international investigations/trials/meetings to promote the advancement of these fields. Finally, all members of my group are deeply invested in the training/education of our house staff and fellows. Our program is personally responsible for the in-depth training of 3 ACGME AHF, Tx and MCS fellows annually.

B. Positions and Honors

Positions and Employment

Sr Partner, University Cardiovascular Medical Group / Cal Heart Foundation
Professor of Medicine / Cardiology Cedars-Sinai (Smidt) Heart Institute
Professor of Medicine / Cardiology David Geffen-UCLA School of Medicine

Board Certifications

Board Certified in Advanced Heart Failure and Transplant Cardiology
Board Certified in Cardiovascular Disease
Board Certified in Internal Medicine

Other Experience and Professional Memberships

2017 – Present	Abiomed Heart Failure Advisory Board
2019 -- Present	Syncardia (TAH) Medical Advisory Board
2010 – Present	Heart Transplant Executive Committee
2010 – Present	Heart Transplant Selection Committee
2010 – Present	MCS PI Committee Chairman
2010 – Present	MCS Core Committee
2010 – Present	Mechanical Circulatory Support Executive Committee
2010 – Present	Heart Failure Research Steering Committee

C. Contributions to Science

As Director of the MCS program and Cedars-Sinai (Smidt) Heart Institute, I have strived to promote the benefits of MCS to patients with ESHD/cardiogenic shock either as bridge to transplant or destination (alternative to Tx) therapy. Our outcomes have improved over the years with survival and successful bridging of our transplant patients that are equal to, if not higher, than expected despite the high acuity of patients transferred to our tertiary center. We have participated in numerous clinical investigations resulting in a variety of presentations, abstracts and manuscripts (see references) at national and international meetings that have contributed to the knowledge and experience of this rapidly growing field.

D. Additional Information: Research Support and/or Scholastic Performance

Ongoing Research Support

Janssen & Janssen LLC	Moriguchi (site PI)	03/09/2016- 02/29/2020
AC-055-205 - to evaluate the effect of the study drug, macitentan, on the properties and function of the heart and on the blood pressure in the pulmonary arteries and to find out more about the safety of the study drug in subjects with PH after LVAD implantation.		

Montreal Heart Institute	Moriguchi (site PI)	11/01/2019 – 10/31/2020
TAH Registry – a multicenter, retrospective registry is to review TAH patient data to better understand the profile of patients selected for TAH implant and timing of the implant as factors in post-implant outcomes and post-transplant outcomes		

Syncardia	Trento (site PI)	07/21/2015 to present
Syncardia 70 cc Temporary Total Artificial Heart for Destination Therapy Study Role: Co-Investigator		

Syncardia	Trento (site PI)	07/21/2015 to present
Syncardia 50 cc Temporary Total Artificial Heart for Destination Therapy Study Role: Co-Investigator		

Abbott Ramzy (site PI) 11/13/2015 to present
MOMENTUM 3 (Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy with HeartMate 3™
Role: Co-Investigator

Abbott Ramzy (site PI) 11/11/2016 to present
MOMENTUM 3 CAP Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy with HeartMate 3™ Continued Access Protocol: Post-Approval Continued Follow-up
Role: Co-Investigator

NIH/Duke University Kransdorf (Site PI) 11/01/17-Present
Entresto™ (LCZ696) In Advanced Heart Failure (Life Study). The purpose of this study is to evaluate the effects of LCZ696 (Entresto) compared to valsartan by evaluating NT-proBNP levels. The hypothesis is that patients with symptomatic heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve NT-proBNP levels. The study is a randomized, double-blinded trial of advanced heart failure subjects.
Role: Co-Investigator

Amgen Chang (Site PI) 06/01/18 - Present
GALACTIC: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction
Role: Co-Investigator